At the forefront of breast cancer prevention and treatment, the Wellend Clinic has begun recruitment for two very exciting new breast cancer trials. Leading US-based biopharmaceutical company GTx, Inc. (NASDAQ:GTXI) chose Wellend to partner with in these concurrent phase 2 trials due to Wellend’s specialisation in the hormonal management of breast disease, one of the two centres in Australia to undertake the trials.

The trial is currently recruiting women who have both hormonally sensitive and traditionally thought of hormonally insensitive breast cancers. Participants will be given an oral treatment which binds to the androgen receptor which is present even in oestrogen and and progesterone receptor negative breast cancers. The trial is looking at using a synthetic hormone called a SARM (selective androgen receptor modulator) in women with advanced breast cancer. The SARM is a very well tolerated drug which attaches to the androgen receptor and is able to shut down the breast cancer cells from dividing.

The trial aims to determine whether this treatment will slow the progress of these advanced breast cancers.

About Wellend:

The Wellend Clinic, located at Attunga House at Burnside War Memorial Hospital (Adelaide, South Australia), is a state-of-the-art breast health specialist clinic, focused on breast cancer prevention and individualised risk management. The Wellend Clinic focuses on the treatment (diagnostic and therapeutic) of women with high breast density and management of women at high risk of breast cancer. High breast density is a leading independent risk factor for getting breast cancer and primary cause of missed cancers during routine screening.

About GTx:

GTx is dedicated to developing novel targeted hormonal therapies to provide better medicines for patients. GTx focus on the development of small molecules that selectively modulate the effects of certain hormones produced by the body. GTx are developing selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of serious diseases, including breast cancer, stress urinary incontinence and Duchenne muscular dystrophy. To further explore treatments targeting diseases caused by abnormal androgen receptor signaling, GTx have a preclinical program to develop selective androgen receptor degraders (SARDs) for prostate cancer patients who no longer respond to androgen deprivation therapy.

Women interested in finding out more about this trial are welcome to contact the clinic on 1300 652 028.